PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
Phase 4
Completed
- Conditions
- Cardiovascular Disease
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4732
- Registration Number
- NCT00147602
- Locations
- π»πͺ
Pfizer Investigational Site, Caracas, Venezuela
Time To Efficacy and Onset Of Action Of Linezolid
Phase 4
Completed
- Conditions
- Gram-Positive Bacterial InfectionsSkin and Connective Tissue Diseases
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 118
- Registration Number
- NCT00147511
IGF1 Generation Test
Phase 4
Completed
- Conditions
- Growth Hormone Deficiency
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2007-06-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT00145457
- Locations
- π«π·
Pfizer Investigational Site, Toulouse Cedex 9, France
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.
Phase 3
Terminated
- Conditions
- Hyperlipoproteinemia Type III
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT00145431
- Locations
- π¨π¦
Pfizer Investigational Site, Quebec, Canada
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00143104
- Locations
- πΊπΈ
Pfizer Investigational Site, San Antonio, Texas, United States
Morphine-Sparing Effect And Safety Of Parecoxib Administered Intravenously For The Treatment Of Postoperative Pain
Phase 3
Completed
- Conditions
- Pain, Postoperative
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 220
- Registration Number
- NCT00143169
- Locations
- π¨π³
Pfizer Investigational Site, Shanghai, China
Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
Phase 2
Terminated
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00143091
- Locations
- π·πΊ
Pfizer Investigational Site, St.-Petersburg, Russian Federation
Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2012-01-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 298
- Registration Number
- NCT00143390
- Locations
- π―π΅
Pfizer Investigational Site, Shizuoka, Japan
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 91
- Registration Number
- NCT00142103
- Locations
- πΊπΈ
Pfizer Investigational Site, Richmond, Virginia, United States
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
Phase 3
Completed
- Conditions
- Epilepsies, PartialEpilepsy, Complex Partial
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2006-07-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00143143
- Locations
Pfizer Investigational Site
Β© Copyright 2025. All Rights Reserved by MedPath